Announcement PDF RNS Number : 2196O N4 Pharma PLC 29 May 2020 29 May 2020 N4 Pharma plc ("N4 Pharma", the "Company" or the "Group") Total Voting Rights N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces the Company's issued ordinary share capital as at the date of this announcement comprises 152,193,787 ordinary shares, with one voting right each. The Company does not hold any ordinary shares in treasury. Therefore, the total number of ordinary shares and voting rights in the Company is 152,193,787. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules. Enquiries: N4 Pharma Plc Nigel Theobald, CEO Via Scott PR Allenby Capital Limited James Reeve/Asha Chotai Tel: +44(0)203 328 5656 Turner Pope Investments (TPI) Ltd Andrew Thacker Tel: +44(0)20 3657 0050 Scott PR Georgia Smith Tel: +44(0)1477 539 539 About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END TVRKKFBQFBKKCPB